Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells

MK2 is a therapeutic target for high-risk multiple myeloma

(2018) Chunyan Gu et al.   HAEMATOLOGICA

Differential Expression and Clinical Significance of Transforming Growth Factor-Beta Isoforms in GBM Tumors

(2018) Laurent-Olivier Roy et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

New therapeutic strategies to treat human cancers expressing mutant p53 proteins

(2018) Giovanni Blandino et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

MK2 is a therapeutic target for high-risk multiple myeloma

(2018) Chunyan Gu et al.   HAEMATOLOGICA

Mutant p53 as a target for cancer treatment

(2017) Michael J. Duffy et al.   EUROPEAN JOURNAL OF CANCER

Thioridazine enhances sensitivity to carboplatin in human head and neck cancer cells through downregulation of c-FLIP and Mcl-1 expression

(2017) Seung Un Seo et al.   Cell Death & Disease

Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme

(2017) Dorota Lubanska et al.   Drugs in research & development

Transforming growth factor-β1 contributes to oxaliplatin resistance in colorectal cancer via epithelial to mesenchymal transition

(2017) Liang Mao et al.   Oncology Letters

Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators

(2017) Alessandra Tolomelli et al.   Cancers

Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).

(2017) Andreas Du Bois et al.   JOURNAL OF CLINICAL ONCOLOGY

The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy

(2017) Tsutomu Iwata et al.   PLoS One

Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth

(2016) M Aggarwal et al.   CELL DEATH AND DIFFERENTIATION

Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy

(2016) Chao He et al.   CHEMOTHERAPY

Molecular mechanisms for tumour resistance to chemotherapy

(2016) Shu-Ting Pan et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma

(2016) Yusuke Furukawa et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword

(2016) Roberta Visconti et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Reactivation of mutant p53 by capsaicin, the major constituent of peppers

(2016) Alessia Garufi et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Synthesis of Novel c(AmpRGD)–Sunitinib Dual Conjugates as Molecular Tools Targeting the αvβ3 Integrin/VEGFR2 Couple and Impairing Tumor-Associated Angiogenesis

(2016) Andrea Sartori et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial

(2016) Mustafa Khasraw et al.   JOURNAL OF NEURO-ONCOLOGY

Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition

(2016) Marco Cordani et al.   Molecular Oncology

Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer

(2016) Bowen Du et al.   MOLECULES

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer

(2016) Dawid Walerych et al.   NATURE CELL BIOLOGY

DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway

(2016) Alejandro Parrales et al.   NATURE CELL BIOLOGY

Integrin-based therapeutics: biological basis, clinical use and new drugs

(2016) Klaus Ley et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors

(2016) Fei Huang et al.   NUCLEIC ACIDS RESEARCH

MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents

(2016) M Y Shah et al.   ONCOGENE

YM155, a small molecule inhibitor of survivin expression, sensitizes cancer cells to hypericin-mediated photodynamic therapy

(2016) Katarína Gyurászová et al.   PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting

(2016) Karolina N. Dziadkowiec et al.   Przeglad Menopauzalny

Bcl-xL is an oncogenic driver in colorectal cancer

(2016) Anna-Lena Scherr et al.   Cell Death & Disease

Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs

(2016) Eun-Ae Kim et al.   Oncotarget

Wnt5a Increases Properties of Lung Cancer Stem Cells and Resistance to Cisplatin through Activation of Wnt5a/PKC Signaling Pathway

(2016) Jiali Yang et al.   Stem Cells International

Wnt5a Signaling in Cancer

(2016) Marwa Asem et al.   Cancers

Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways

(2016) Sue Haupt et al.   Frontiers in Oncology

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)

(2015) J. Vansteenkiste et al.   ANNALS OF ONCOLOGY

Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells

(2015) Lina Yang et al.   CANCER LETTERS

The Stress Kinase p38  as a Target for Cancer Therapy

(2015) A. Igea et al.   CANCER RESEARCH

Spatial dynamics of TRAIL death receptors in cancer cells

(2015) Julianne D. Twomey et al.   DRUG RESISTANCE UPDATES

The risk of prostate cancer for men on aspirin, statin or antidiabetic medications

(2015) Tobias Nordström et al.   EUROPEAN JOURNAL OF CANCER

Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity

(2015) Milan Bruncko et al.   JOURNAL OF MEDICINAL CHEMISTRY

Holothurian glycosaminoglycan inhibits metastasis via inhibition of P-selectin in B16F10 melanoma cells

(2015) Zhiqiang Yue et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Targeting Mitosis in Cancer: Emerging Strategies

(2015) Carmen Dominguez-Brauer et al.   MOLECULAR CELL

Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells

(2015) JINPENG LI et al.   Molecular Medicine Reports

Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance

(2015) Laetitia Seguin et al.   TRENDS IN CELL BIOLOGY

Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation

(2015) C J Henrich et al.   Cell Death & Disease

The ZNF304-integrin axis protects against anoikis in cancer

(2015) Burcu Aslan et al.   Nature Communications

Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns

(2015) Ingrid Cifola et al.   Oncotarget

A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer

(2015) Jai-Hee Moon et al.   Oncotarget

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients

(2015) Maria Serova et al.   Oncotarget

Whole Exome Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in Chinese Patients with Lung Squamous Cell Carcinoma

(2015) Chenguang Li et al.   Scientific Reports

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib

(2015) Barbara Muz et al.   Biomed Research International

Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells

(2015) Rachana Trivedi et al.   Frontiers in Oncology

Regulation of Mutant p53 Protein Expression

(2015) Reshma Vijayakumaran et al.   Frontiers in Oncology

Aurora-A promotes chemoresistance in hepatocelluar carcinoma by targeting NF-kappaB/microRNA-21/PTEN signaling pathway

(2015) Kai Zhang et al.   Oncotarget

WNT5A-NFAT Signaling Mediates Resistance to Apoptosis in Pancreatic Cancer

(2015) Heidi Griesmann et al.   NEOPLASIA

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

(2014) J. B. Vermorken et al.   ANNALS OF ONCOLOGY

Enhancement of tumor-TRAIL susceptibility by modulation of autophagy

(2014) Wen Hou et al.   Autophagy

Aurora-A controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks

(2014) Huizhen Sun et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial–mesenchymal transition

(2014) Chul-Yong Park et al.   CANCER LETTERS

CBP-93872 Inhibits NBS1-Mediated ATR Activation, Abrogating Maintenance of the DNA Double-Strand Break-Specific G2 Checkpoint

(2014) T. Hirokawa et al.   CANCER RESEARCH

The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells

(2014) Frederik Köpper et al.   CELL CYCLE

Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles

(2014) Obinna Ubah et al.   CURRENT PHARMACEUTICAL DESIGN

WNT5A modulates cell cycle progression and contributes to the chemoresistance in pancreatic cancer cells

(2014) Wei Wei et al.   Hepatobiliary & Pancreatic Diseases International

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors

(2014) Jamie N. Anastas et al.   JOURNAL OF CLINICAL INVESTIGATION

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

(2014) Roger Stupp et al.   LANCET ONCOLOGY

Effects of the small-molecule inhibitor of integrin α4, TBC3486, on pre-B-ALL cells

(2014) Y T Hsieh et al.   LEUKEMIA

A Novel Small Molecule Aurora Kinase Inhibitor Attenuates Breast Tumor-Initiating Cells and Overcomes Drug Resistance

(2014) F.-M. Zheng et al.   MOLECULAR CANCER THERAPEUTICS

Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer

(2014) M. Marin-Aguilera et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of the p38 MAPK pathway sensitizes human gastric cells to doxorubicin treatment in vitro and in vivo

(2014) WEI TAN et al.   Molecular Medicine Reports

The aurora kinases in cell cycle and leukemia

(2014) B Goldenson et al.   ONCOGENE

Small-molecule SMAC mimetics as new cancer therapeutics

(2014) Longchuan Bai et al.   PHARMACOLOGY & THERAPEUTICS

p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance

(2014) Valentina Grossi   WORLD JOURNAL OF GASTROENTEROLOGY

Integrin inhibition promotes atypical anoikis in glioma cells

(2014) M Silginer et al.   Cell Death & Disease

Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway

(2014) R Trivedi et al.   Cell Death & Disease

Highlights of the Latest Advances in Research on CDK Inhibitors

(2014) Jonas Cicenas et al.   Cancers

Current clinical trials with polo-like kinase 1 inhibitors in solid tumors

(2013) Hyungshin Yim   ANTI-CANCER DRUGS

Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation

(2013) Mi Jin Yoon et al.   CARCINOGENESIS

Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors

(2013) A. F. Schott et al.   CLINICAL CANCER RESEARCH

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

(2013) Prithviraj Bose et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

(2013) Neil E. Bhola et al.   JOURNAL OF CLINICAL INVESTIGATION

The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells

(2013) Takuro Hayashi et al.   JOURNAL OF NEURO-ONCOLOGY

Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications

(2013) C C Bjorklund et al.   LEUKEMIA

PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa

(2013) Manujendra N. Saha et al.   MOLECULAR CANCER THERAPEUTICS

Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance

(2013) C. Haider et al.   MOLECULAR CANCER THERAPEUTICS

Small molecule induced reactivation of mutant p53 in cancer cells

(2013) Xiangrui Liu et al.   NUCLEIC ACIDS RESEARCH

Gamma secretase inhibitors of Notch signaling

(2013) Clodia Osipo et al.   OncoTargets and Therapy

Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation

(2013) H. Walczak   Cold Spring Harbor Perspectives in Biology

DNA Damage Sensing by the ATM and ATR Kinases

(2013) A. Marechal et al.   Cold Spring Harbor Perspectives in Biology

Small molecule sensitization to TRAIL is mediated via nuclear localization, phosphorylation and inhibition of chaperone activity of Hsp27

(2013) G Mellier et al.   Cell Death & Disease

A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response In Vivo

(2013) Sandra Morandell et al.   Cell Reports

Mechanisms and insights into drug resistance in cancer

(2013) Hiba Zahreddine et al.   Frontiers in Pharmacology

Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205

(2012) Martin Puhr et al.   AMERICAN JOURNAL OF PATHOLOGY

Amurensin G, a novel SIRT1 inhibitor, sensitizes TRAIL-resistant human leukemic K562 cells to TRAIL-induced apoptosis

(2012) Hak-Bong Kim et al.   BIOCHEMICAL PHARMACOLOGY

Cyclin dependent kinases in cancer

(2012) Miriam Canavese et al.   CANCER BIOLOGY & THERAPY

Aurora A kinase (AURKA) in normal and pathological cell division

(2012) Anna S. Nikonova et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma

(2012) Paola Neri et al.   CURRENT CANCER DRUG TARGETS

Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism

(2012) Kevin R. Kelly et al.   INTERNATIONAL JOURNAL OF CANCER

Diallyl trisulfide sensitizes human melanoma cells to TRAIL-induced cell death by promoting endoplasmic reticulum-mediated apoptosis

(2012) MAYUMI MURAI et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

New Insights into p53 Signaling and Cancer Cell Response to DNA Damage: Implications for Cancer Therapy

(2012) Razmik Mirzayans et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Targeting Mutant p53 in Human Tumors

(2012) Brian D. Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of CD44 in tumour progression and strategies for targeting

(2012) Lalit Mohan Negi et al.   JOURNAL OF DRUG TARGETING

p53 mutations in cancer

(2012) Patricia A. J. Muller et al.   NATURE CELL BIOLOGY

Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes

(2012) Zhi Jiang Zang et al.   NATURE GENETICS

Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation

(2011) Carlos Mas-Moruno et al.   Anti-Cancer Agents in Medicinal Chemistry

Identification of a checkpoint modulator with synthetic lethality to p53 mutants

(2011) Naoki Harada et al.   ANTI-CANCER DRUGS

P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment

(2011) A. K. Azab et al.   BLOOD

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications

(2011) Klaus Podar et al.   BRITISH JOURNAL OF HAEMATOLOGY

5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells

(2011) Jian-Feng Yang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells

(2011) Jing Zhao et al.   CANCER LETTERS

EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells

(2011) Chul-Yong Park et al.   CANCER SCIENCE

Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway

(2011) Ilana Chefetz et al.   CELL CYCLE

PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53

(2011) R. Zandi et al.   CLINICAL CANCER RESEARCH

Peptides or Small Molecules? Different Approaches to Develop More Effective CDK Inhibitors

(2011) D. Cirillo et al.   CURRENT MEDICINAL CHEMISTRY

EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung

(2011) Chul-Yong Park et al.   EUROPEAN JOURNAL OF CANCER

Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin

(2011) Britta Wagner   INTERNATIONAL JOURNAL OF ONCOLOGY

Calpain-mediated Processing of p53-associated Parkin-like Cytoplasmic Protein (PARC) Affects Chemosensitivity of Human Ovarian Cancer Cells by Promoting p53 Subcellular Trafficking

(2011) Michael G. Woo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation

(2011) Yongxing Wang et al.   JOURNAL OF CLINICAL INVESTIGATION

Apoptosis in cancer: from pathogenesis to treatment

(2011) Rebecca SY Wong   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

(2011) J. Chen et al.   MOLECULAR CANCER THERAPEUTICS

The roles of TGF-β signaling in carcinogenesis and breast cancer metastasis

(2011) Takeshi Imamura et al.   Breast Cancer

Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters

(2011) M Saxena et al.   Cell Death & Disease

BH3-only proteins: Orchestrators of apoptosis

(2010) Aisha Shamas-Din et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Targeting c-FLIP in cancer

(2010) Sarah Shirley et al.   CANCER LETTERS

Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma

(2010) S. Paillas et al.   CANCER RESEARCH

Secondary mutations of BRCA1/2 and drug resistance

(2010) Kiranjit K. Dhillon et al.   CANCER SCIENCE

The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs

(2010) Silvia Di Agostino et al.   CELL CYCLE

Identification of c-FLIPL and c-FLIPS as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells

(2010) C. Haag et al.   GUT

The role of c-FLIPL in ovarian cancer: Chaperoning tumor cells from immunosurveillance and increasing their invasive potential

(2010) Ahmed El-Gazzar et al.   GYNECOLOGIC ONCOLOGY

Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer

(2010) Stefania Bellone et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

(2010) Kevin R. Kelly et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Smac mimetics: implications for enhancement of targeted therapies in leukemia

(2010) E Weisberg et al.   LEUKEMIA

ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells

(2010) Aurélie Thollet et al.   Molecular Cancer

The DNA Damage Response: Making It Safe to Play with Knives

(2010) Alberto Ciccia et al.   MOLECULAR CELL

Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase

(2010) H Yamamoto et al.   ONCOGENE

c-FLIP Degradation Mediates Sensitization of Pancreatic Cancer Cells to TRAIL-Induced Apoptosis by the Histone Deacetylase Inhibitor LBH589

(2010) John Kauh et al.   PLoS One

Aurora-A Contributes to Radioresistance by Increasing NF-κB DNA Binding

(2010) Eun-Taex Oh et al.   RADIATION RESEARCH

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

(2010) Cynthia X. Ma et al.   TRENDS IN MOLECULAR MEDICINE

Crossing the endothelium

(2010) Julia Woodward   Cell Adhesion & Migration

The roles of cell adhesion molecules in tumor suppression and cell migration

(2010) Mei Chung Moh et al.   Cell Adhesion & Migration

Molecular interactions in cancer cell metastasis

(2009) Susan A. Brooks et al.   ACTA HISTOCHEMICA

Cell Adhesion Molecules: Role and Clinical Significance in Cancer

(2009) Nektaria Makrilia et al.   CANCER INVESTIGATION

Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma

(2009) W. Sakai et al.   CANCER RESEARCH

Caspases and Kinases in a Death Grip

(2009) Manabu Kurokawa et al.   CELL

Epithelial-Mesenchymal Transitions in Development and Disease

(2009) Jean Paul Thiery et al.   CELL

Wnt-5a-CKIα Signaling Promotes β-Catenin/E-Cadherin Complex Formation and Intercellular Adhesion in Human Breast Epithelial Cells

(2009) Catharina Medrek et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer

(2009) Emma Dean et al.   JOURNAL OF CLINICAL ONCOLOGY

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

The DNA-damage response in human biology and disease

(2009) Stephen P. Jackson et al.   NATURE

Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis

(2009) J M R Lambert et al.   ONCOGENE

CUB-Domain-Containing Protein 1 Regulates Peritoneal Dissemination of Gastric Scirrhous Carcinoma

(2008) Takamasa Uekita et al.   AMERICAN JOURNAL OF PATHOLOGY

Cytoprotective effects of IAPs revealed by a small molecule antagonist

(2008) Stefanie Galbán et al.   BIOCHEMICAL JOURNAL

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

(2008) N Bucher et al.   BRITISH JOURNAL OF CANCER

Anoikis resistance and tumor metastasis

(2008) Craig D. Simpson et al.   CANCER LETTERS

Mutational analyses of c-FLIPR, the only murine short FLIP isoform, reveal requirements for DISC recruitment

(2008) N Ueffing et al.   CELL DEATH AND DIFFERENTIATION

WNT5A Expression Increases during Melanoma Progression and Correlates with Outcome

(2008) P. D. Da Forno et al.   CLINICAL CANCER RESEARCH

ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology

(2008) R. Schmidmaier et al.   CURRENT MEDICINAL CHEMISTRY

Completing the family portrait of the anti-apoptotic Bcl-2 proteins: Crystal structure of human Bfl-1 in complex with Bim

(2008) Maria Dolores Herman et al.   FEBS LETTERS

Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins

(2008) David S. Ziegler et al.   JOURNAL OF CLINICAL INVESTIGATION

Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells

(2008) Tamer E Fandy et al.   Molecular Cancer

Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells

(2008) C. Wilson et al.   MOLECULAR CANCER THERAPEUTICS

Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region

(2008) K. Kandasamy et al.   MOLECULAR CANCER THERAPEUTICS

17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis

(2008) Markus David Siegelin et al.   NEUROBIOLOGY OF DISEASE

IAP-targeted therapies for cancer

(2008) E C LaCasse et al.   ONCOGENE